Pilatus Biosciences has dosed its first patient in Hong Kong in the ongoing Phase 1 study of PLT012, an investigational CD36-targeting antibody for advanced cancers. The new hepatocellular carcinoma cohort will examine safety, early clinical activity and biomarkers associated with tumor metabolism and immune suppression.
AbelZeta’s C-CAR031 study shows a 44.4% response rate in advanced liver cancer, but durability and resistance remain key tests.
Confluence Genetics launches Cas-CLEAR, a Cas12a2 CRISPR platform designed to kill mutation-bearing cancer cells. Explore the evidence and risks.
Find out how Oricell’s Ori-C101 CAR-T data could reshape expectations for late-line liver cancer treatment after ASCO 2026.
Could AstraZeneca’s latest ASCO 2026 cancer data reshape future treatment sequencing in liver and breast oncology? Read the full analysis.
Post-ICI liver cancer has few strong options. Agenus’ BOT plus BAL data raise the next question: can durability survive larger trials?
RNA editing just gained a liver cancer spotlight. Rznomics must now prove RZ-001 can turn early response signals into durable clinical value.
Rznomics reported interim RZ-001 liver cancer data at AACR 2026. Read why the efficacy and safety signals could matter for hepatocellular carcinoma.
Abbisko Therapeutics won EMA orphan drug designation for irpagratinib in liver cancer. Read what this changes for FGFR4-targeted therapy.
Pilatus Biosciences earns FDA Fast Track for PLT012 in liver cancer. Read why CD36 targeting could reshape immunotherapy development.